-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Why PAVmed Shares Are Falling Today
Why PAVmed Shares Are Falling Today
PAVmed Inc. (NASDAQ:PAVM) shares are trading lower after the company announced a workforce reduction of roughly 20% alongside other cost-cutting measures.
What happened: PAVmed and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ:LUCD) and Veris Health Inc., announced Tuesday via a strategic business update that the companies have implemented a workforce reduction of 20%, which aims to reduce quarterly cash burn rate by at least 25%.
PAVmed plans to prioritize near-term commercialization for Lucid and Veris Health through:
- Both continued research and product development for Lucid and Veris
- Continued limited business development opportunities focused on high-value, near-term, accretive opportunities.
- Pausing or halting all other product development activities, including CarpX, PortIO, and NextFlo
- Pursuing additional cost-cutting measures such as not paying annual cash bonuses.
Lishan Aklong, M.D., PAVmed's and Lucid's Chairman and CEO, notes, "We have engaged in a systematic effort to maximize our cash runaway and protect our long-term shareholder interests while executing our strategic objectives in what remain challenging market conditions."
PAVmed Inc is a medical device company engaged in advancing a pipeline of medical technologies from concept to commercialization using a business model focused on capital and time efficiency.
According to data from Benzinga Pro, PAVmed Inc. shares were down 18.7%, trading at $0.51 at the time of publication. It has a 52-week high of $0.62 and a 52-week low of $0.5086.
PAVmed Inc. (NASDAQ:PAVM) shares are trading lower after the company announced a workforce reduction of roughly 20% alongside other cost-cutting measures.
PavMed Inc. 纳斯达克股票代码:PAVM)的股价走低,此前该公司宣布裁员约20%,同时采取其他削减成本的措施。
What happened: PAVmed and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ:LUCD) and Veris Health Inc., announced Tuesday via a strategic business update that the companies have implemented a workforce reduction of 20%, which aims to reduce quarterly cash burn rate by at least 25%.
发生了什么: PavMed 及其子公司, Lucid 诊断公司 (纳斯达克股票代码:LUCD)和 Veris Health.,周二在战略业务更新中宣布,两家公司已实施裁员20%,目标是将季度现金消耗率降低至少25%。
PAVmed plans to prioritize near-term commercialization for Lucid and Veris Health through:
PavMed 计划通过以下方式优先让 Lucid 和 Veris Health 在短期内实现商业化:
- Both continued research and product development for Lucid and Veris
- Continued limited business development opportunities focused on high-value, near-term, accretive opportunities.
- Pausing or halting all other product development activities, including CarpX, PortIO, and NextFlo
- Pursuing additional cost-cutting measures such as not paying annual cash bonuses.
- Lucid 和 Veris 都在继续研究和产品开发
- 持续有限的业务发展机会集中在高价值、近期的增值机会上。
- 暂停或停止所有其他产品开发活动,包括 carPX、PortIO 和 NextFlo
- 采取其他削减成本的措施,例如不支付年度现金奖金。
Lishan Aklong, M.D., PAVmed's and Lucid's Chairman and CEO, notes, "We have engaged in a systematic effort to maximize our cash runaway and protect our long-term shareholder interests while executing our strategic objectives in what remain challenging market conditions."
Lishan Aklong,医学博士.,PavMed和Lucid的董事长兼首席执行官指出:“我们一直在系统地努力最大限度地利用现金流失并保护我们的长期股东利益,同时在仍然充满挑战的市场条件下执行我们的战略目标。”
PAVmed Inc is a medical device company engaged in advancing a pipeline of medical technologies from concept to commercialization using a business model focused on capital and time efficiency.
PavMed Inc是一家医疗器械公司,致力于使用注重资本和时间效率的商业模式,将医疗技术从概念推向商业化。
According to data from Benzinga Pro, PAVmed Inc. shares were down 18.7%, trading at $0.51 at the time of publication. It has a 52-week high of $0.62 and a 52-week low of $0.5086.
根据Benzinga Pro的数据,PavMed Inc.的股价下跌了18.7%,在发布时交易价格为0.51美元。它的52周高点为0.62美元,52周低点为0.5086美元。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧